References
Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP (2004) Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30:131–156
Köller H, Kieseier BC, Jander S, Hartung HP (2005) Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352:1343–1356
Stangel M, Hartung HP, Marx P, Gold R (1998) Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci 153:203–214
Toyka KV, Gold R (2003) The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents. Neurology 60:S2–7
Dalakas MC (2004) Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291:2367–2375
Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J (2000) The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 20:94–100
Gardulf A, Hammarstrom L, Smith CI (1991) Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 338:162–166
Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, Gardulf A, Eichmann F, Haag S, Massion C, Ochs HD (2006) Health-related quality of life and treatment satisfaction in north american patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 26:65–72
Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force (1991) Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 41:617–618
Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA (2002) Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 72:596–601
Author information
Authors and Affiliations
Corresponding author
Additional information
Received in revised form: 16 March 2006
Rights and permissions
About this article
Cite this article
Köller, H., Schroeter, M., Feischen, H. et al. Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol 253, 1505–1506 (2006). https://doi.org/10.1007/s00415-006-0258-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-006-0258-0